Australia markets closed

Danaher Corporation (DHR)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
243.54-1.25 (-0.51%)
At close: 04:00PM EDT
246.91 +3.37 (+1.38%)
After hours: 07:38PM EDT

Danaher Corporation

2200 Pennsylvania Avenue, North West
Suite 800 West
Washington, DC 20037-1701
United States
202 828 0850
https://www.danaher.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees61,000

Key executives

NameTitlePayExercisedYear born
Mr. Steven M. RalesCo-Founder & ChairmanN/AN/A1951
Mr. Rainer M. BlairPresident, CEO & Director5.33MN/A1964
Mr. Mitchell P. RalesCo-Founder & DirectorN/AN/A1957
Mr. Matthew R. McGrewCFO & Executive VP2.56MN/A1972
Dr. Jose-Carlos Gutierrez-Ramos Ph.D.Senior VP & Chief Science Officer2.09MN/A1962
Ms. Georgeann F. CoucharaSenior Vice President of Human Resources1.66MN/A1977
Mr. Joakim WeidemanisExecutive Officer2.76M6.5M1969
Mr. Christopher M. BoudaVP & Chief Accounting OfficerN/AN/AN/A
Mr. John BedfordVice President of Investor RelationsN/AN/AN/A
Mr. Brian W. EllisSenior VP, General Counsel & Chief Compliance Officer1.93MN/A1967
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Corporate governance

Danaher Corporation’s ISS governance QualityScore as of 1 July 2024 is 8. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.